TICKERNOMICS Sign up
Last Update: 2024-12-27 15:24:57
ArriVent BioPharma Inc. ( AVBP ) https://www.arrivent.com
27.58USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
AVBP
0.00%
SPY
32.66%
AVBP
0.00%
SPY
108.59%
AVBP
0.00%
SPY
302.52%
AVBP
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
926.19
643.54
0.07
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-11.43
0.00
3.34
0.00
0.00
-8.97
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-1.57
-58.19
0.00
Other Earnings and Cash Flow Stats:
ArriVent BioPharma Inc. ( AVBP ) Net Income TTM ($MM) is -81.05
ArriVent BioPharma Inc. ( AVBP ) Operating Income TTM ($MM) is -93.72
ArriVent BioPharma Inc. ( AVBP ) Owners' Earnings Annual ($MM) is 0.00
ArriVent BioPharma Inc. ( AVBP ) Current Price to Owners' Earnings ratio is 0.00
ArriVent BioPharma Inc. ( AVBP ) EBITDA TTM ($MM) is -47.48
ArriVent BioPharma Inc. ( AVBP ) EBITDA Margin is 0.00%
Capital Allocation:
ArriVent BioPharma Inc. ( AVBP ) has paid 0.00 dividends per share and bought back -1.625153 million shares in the past 12 months
ArriVent BioPharma Inc. ( AVBP ) has increased its debt by 0.213 million USD in the last 12 months
Capital Structure:
ArriVent BioPharma Inc. ( AVBP ) Interest-bearing Debt ($MM) as of last quarter is 0
ArriVent BioPharma Inc. ( AVBP ) Annual Working Capital Investments ($MM) are -4
ArriVent BioPharma Inc. ( AVBP ) Book Value ($MM) as of last quarter is 277
ArriVent BioPharma Inc. ( AVBP ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
ArriVent BioPharma Inc. ( AVBP ) has 282 million in cash on hand as of last quarter
ArriVent BioPharma Inc. ( AVBP ) has 15 million of liabilities due within 12 months, and long term debt 0 as of last quarter
ArriVent BioPharma Inc. ( AVBP ) has 33 common shares outstanding as of last quarter
ArriVent BioPharma Inc. ( AVBP ) has 0 million USD of preferred stock value
Academic Scores:
ArriVent BioPharma Inc. ( AVBP ) Altman Z-Score is 35.54 as of last quarter
ArriVent BioPharma Inc. ( AVBP ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
ArriVent BioPharma Inc. ( AVBP ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of ArriVent BioPharma Inc. ( AVBP ) for the amount of $ on
9.84% of ArriVent BioPharma Inc. ( AVBP ) is held by insiders, and 77.39% is held by institutions
ArriVent BioPharma Inc. ( AVBP ) went public on 2024-01-26
Other ArriVent BioPharma Inc. ( AVBP ) financial metrics:
FCF:-68.97
Unlevered Free Cash Flow:0.00
EPS:-2.45
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-29.64
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ArriVent BioPharma Inc. ( AVBP ) :
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.